AstraZeneca (LON:AZN) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

AstraZeneca PLC (LON:AZN) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as £119.08 ($149.88). AstraZeneca shares last traded at £117.08 ($147.36), with a volume of 2,988,152 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AZN. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($176.21) target price on shares of AstraZeneca in a report on Friday, November 22nd. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.76) target price on shares of AstraZeneca in a report on Monday, January 27th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of GBX 7,542.80 ($94.94).

AstraZeneca Stock Performance

The firm has a market capitalization of £225.27 billion, a PE ratio of 32.09, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The company’s fifty day moving average price is £108.87 and its two-hundred day moving average price is £114.78.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Tony Mok bought 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($159.60) per share, with a total value of £190,200 ($239,395.85). Insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.